Another well-known issue of PI3K/AKT SNIs is emergence of treatment-induced hyperglycaemia and hyperinsulinemia, which are propagated as ‘on-target, off tumour’ effects where blockade of PI3K/AKT/GLUT4 signalling prevents glucose uptake by peripheral tissues [19]. The gene discussed is PIK3CB; the disease is Hyperinsulinemia.